CardioKinetix Inc. said Tuesday it has raised $44 million in a two-tranche Series E financing.
The Menlo Park-based medical device company makes implant technology to treat heart failure. It plans to use the funds to further its clinical studies and for commercialization.
Showing posts with label SV Life Sciences. Show all posts
Showing posts with label SV Life Sciences. Show all posts
Tuesday, September 20, 2011
Tuesday, June 7, 2011
Biotech startup Cyterix raises $9.2M Series A
Biotech startup Cyterix Pharmaceuticals Inc. raised $9.2 million from The Column Group and SV Life Sciences in a Series A financing.
The San Francisco company, founded by academics Steve Everett and Paul Ortiz de Montellano and the late biotech entrepreneur John Curd, is working to discover and develop drugs that target certain enzymes that are highly over-expressed in many cancers. Specifically, it targets extra-hepatic cytochrome P450 enzymes.
The San Francisco company, founded by academics Steve Everett and Paul Ortiz de Montellano and the late biotech entrepreneur John Curd, is working to discover and develop drugs that target certain enzymes that are highly over-expressed in many cancers. Specifically, it targets extra-hepatic cytochrome P450 enzymes.
Subscribe to:
Posts (Atom)